Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Ivo combo beats Tevimbra, but can it beat Keytruda?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
